RenovoRx, Inc. · NASDAQ:RNXT

RenovoRx — Investor Presentation (November 2026)

28 slides from RenovoRx's investor presentation, November 2026

  1. Slide 1: Investor Presentation

    Investor Presentation NASDAQ | RNXT Delivering therapy where it matters® November 2026 © RenovoRx, Inc. All rights reserved. NASDAQ | RNXT

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation and statements of the Company’s management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, i

  3. Slide 3: RenovoRx at a Glance

    RenovoRx at a Glance Commercial-stage company with high margin life sciences business scaling rapidly Driving adoption of FDA-cleared RenovoCath® across 26 U.S. commercial cancer centers (as of 11/5/26) and growing, accelerating market penetration and strengthening commercial momentum. Estimated tar

  4. Slide 4: Proprietary Trans-Arterial Micro-Perfusion (TAMP) Therapy Platform

    Proprietary Trans-Arterial Micro-Perfusion (TAMP) Therapy Platform Enabled by RenovoCath 3 NASDAQ | RNXT

  5. Slide 5: Addressing a Significant Problem in Cancer Treatment

    Addressing a Significant Problem in Cancer Treatment Hypervascular tumors are inadequately treated with Hypovascular tumors = major barrier to chemotherapy current therapies treatment success For example, liver tumors are highly vascularized Many tumors, like pancreatic tumors, bile duct tumors, etc

  6. Slide 6: Illustration of TAMP with RenovoCath

    5 Illustration of TAMP with NASDAQ | RNXT RenovoCath

  7. Slide 7: Mechanism: Trans-Arterial Micro-Perfusion (TAMP)

    Mechanism: Trans-Arterial Micro-Perfusion (TAMP) Mechanism: after vessel isolation, increase in pressure forces drug across the artery wall into the micro-vasculature and into tissue At optimal pressure – tissue pressure is overcome, forcing 70 delivery outside the primary vessel into the tissue 60

  8. Slide 8: TAMP Improves a Drug's Therapeutic Index

    TAMP Improves a Drug’s Therapeutic Index Increases Drug Concentration to IA Reduces Systemic Drug Exposure by 46.6% Target Pathological Site by ~100X1 Compared to IV Administration2 Tissue Concentration Gem (mcg/g) Drug Exposure IA vs. IV route 1500 15 Gemcitabine AUC0-t (h*mcg/mL) 1272.83 1250 10 1

  9. Slide 9: Patient and Physician Experience

    Patient and Physician Experience RenovoCath Other Treatment Options RenovoCath Patient Experience Other Patient Experience  Typically, 5-10 treatments per year with disposable device (no  Traditional systemic gemcitabine + Abraxane: 12 hospital/clinic implant) visits over 4-month period or longer

  10. Slide 10: RenovoCath: A Drug-Delivery Platform Able to Serve Multiple Markets

    RenovoCath: A Drug-Delivery Platform Able to Serve Multiple Markets INITIAL TARGETED ONCOLOGY APPLICATIONS IN UNITED STATES GROWTH POTENTIAL 70,000 67,530 Total Addressable Market (TAM) Expansion Opportunities Could 60,000 Serviceable Addressable Market (SAM)4 Increase SAM: 50,000 • Near-Term: NEW A

  11. Slide 11: Commercial Opportunity: RenovoCath Standalone, FDA-Cleared Drug-Delivery Device

    Commercial Opportunity RenovoCath Standalone, FDA-Cleared Drug-Delivery Device 10 NASDAQ | RNXT

  12. Slide 12: High Margin Large Market Opportunity for RenovoCath Standalone Device

    High Margin Large Market Opportunity for RenovoCath Standalone Device RenovoCath US Market Opportunity Analogous pressure-mediated delivery $8k-$8.5k/unit1 catheter ASPs ~5-10 per Annual average procedures patient2 Patented Highly Defensible Position Annual revenue opportunity $400M3 RenovoRx holds

  13. Slide 13: RenovoCath Go-to-Market Strategy

    RenovoCath Go-to-Market Strategy 2026 Commercialization Ramp Builds on 2025 Limited Market Launch, Delivering Record Revenue Growth Concentrated Market: fewer than 200 hospitals treat majority of estimated patients where RenovoCath is seeing interest in Go-To-Market Strategy utilization Broadening a

  14. Slide 14: RenovoCath Commercialization Update

    RenovoCath Commercialization Update (as of 11/5/26) Commercialization Activities Demonstrate Momentum Building Across Business and Reinforce Confidence into 2027 RenovoCath customers actively treating patients: 26 cancer centers Customer pipeline expansion: Additional RenovoCath >65 total centers cu

  15. Slide 15: Combination Pipeline, Registry & IIT Strategy

    Combination Pipeline, Registry & IIT Strategy Centers can bill for the TAMP procedure regardless of the target tumor or agent administered. RenovoRx is running Phase III TIGeR-PaC (fully enrolled as of August 2026) and supports Investigator Initiated Trials (IITs) and registry studies across agents

  16. Slide 16: Pivotal Phase III TIGeR-PaC Clinical Trial in LAPC

    Pivotal Phase III TIGeR-PaC Clinical Trial (NCT03257033) in Locally Advanced Pancreatic Cancer (LAPC) 15 NASDAQ | RNXT

  17. Slide 17: Significant Unmet Need

    Significant Unmet Need Three FDA approvals for first line pancreatic cancer in the last 10 years showed minimal Median Overall Survival (OS) benefit and increased toxicity1 Gemcitabine + Abraxane Abraxane 38% Grade 3 Abraxane obtained FDA approval in 2013 on a or Higher Neutropenia and 7-week Median

  18. Slide 18: Potential Market Penetration Based on Modest Efficacy from TIGeR-PaC

    Potential Market Penetration Based on Modest Efficacy from TIGeR-PaC Independent interviews suggest oncologists likely to adopt gemcitabine delivered via RenovoCath w/ at least 3–4-month OS benefit and toxicity improvement are met 5 Number of Respondents 4 3 2 1 0 <1 1 month 2 months 3 months 4 mont

  19. Slide 19: TIGeR-PaC Phase III Randomized Trial Design

    TIGeR-PaC Phase III Randomized Trial Design Combination Product Trial for TAMP Delivery of Intra-Arterial (IA) Gemcitabine (IAG) via FDA-Cleared RenovoCath in Locally Advanced Pancreatic Cancer (LAPC) Induction Phase 1:1 RANDOMIZATION PHASE 1◦ Endpoint 4-month treatment protocol: standard of care IV

  20. Slide 20: TAMP: 6-Month Median OS Benefit vs. IV Gemcitabine + Abraxane

    TAMP (IA Gemcitabine via RenovoCath): 6-Month Median OS Benefit vs. IV (Systemic) Gemcitabine + Abraxane TIGeR-PaC phase III first interim analysis Data on 45 patients randomized INDUCTION RANDOMIZED TREATMENT & FOLLOW-UP s • 23 randomized to RenovoCath plus Gemcitabine • 22 randomized to IV gemcita

  21. Slide 21: TAMP via RenovoCath: Fewer AEs and SAEs vs IV Gemcitabine + Abraxane

    TAMP (IA Gem) via RenovoCath: Fewer AEs and SAEs vs IV (systemic) Gemcitabine + Abraxane TIGeR-PaC phase III first interim analysis 65% fewer total AEs and SAEs Fewer AEs in 11/13 categories with greater than 10% in IA vs. IV arm frequency in each arm (All Grades) 300 Adverse Events IV Gem + Pac IA

  22. Slide 22: RNXT Financial Highlights

    RNXT Financial Highlights Record Q3 2026 Revenue of $1.07M, exceeding million-dollar RNXT Daily Performance threshold, up > four-fold YoY 2026 YTD through November 2, 2026  Driven by accelerating commercial adoption 3.00  Nine months ended September 2026 revenue: $2.5M, up 138% YoY; 3Q26 close of

  23. Slide 23: Experienced Management Team

    Experienced Management Team Shaun R. Bagai Leesa Gentry Chief Executive Officer & Board Member Chief Clinical Officer 2  HeartFlow (>$2B IPO)  Evotec  Ardian (Acquired for > $900M)  Otsuka America Pharmaceuticals  Medtronic Vascular  Omnicare Clinical Research  TransVascular (Acquired by Medt

  24. Slide 24: Board of Directors

    Board of Directors Ramtin Agah, MD Laurence J. Marton, MD Executive Chairman, Chief Medical Officer, & Founder Director  Interventional Cardiology, El Camino Hospital  Board: Cellsonics, TOMA Biosciences, xCures  Consultant, Abbott Vascular Shaun R. Bagai Una S. Ryan, PhD, OBE Director & Chief Ex

  25. Slide 25: RenovoRx Scientific Advisory Board

    RenovoRx Scientific Advisory Board Timothy Donahue, MD Karyn A. Goodman, MD, MS  Director of the UCLA Agi Hirshberg Center for Pancreatic  Professor and Vice Chair of Clinical Research, Department of Diseases Radiation Oncology, Icahn School of Medicine at Mount Sinai  Garry Shandling Chair in Pa

  26. Slide 26: RenovoCath Medical Advisory Board

    RenovoCath Medical Advisory Board Nadine Abi-Jaoudeh, MD Mustafa Al-Roubaie, MD  Chief of Interventional Radiology and Director of Clinical  Interventional Radiologist at Moffitt Cancer Center Research in the Department of Radiology at the  Associate Professor of Radiology and Oncologic Sciences

  27. Slide 27: How Hospitals are Using TAMP with RenovoCath in Oncology Management

    How Hospitals are Using TAMP with RenovoCath in Oncology Management* Visit https://ir.renovorx.com/news-events/clinical-news to Learn More CBS News HealthWatch featured Hernando Salcedo, an 83-year-old grandfather with Stage 3 pancreatic cancer who struggled with systemic chemotherapy at Miami Cance

  28. Slide 28: Thank You

    Investor Contact: Thank You ICR Healthcare Stephanie Carrington or Adanna G. Alexander, Ph.D. RenovoRx@ICRHealthcare.com | +1.212.896.1254 Media Contact: StiR Communications Hannah Williams Hannah@stir-communications.com | +1.803.521.1214 © RenovoRx, Inc. All rights reserved. NASDAQ | RNXT

RenovoRx — Investor Presentation (November 2026) on 6ix